Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
- Author:
Se Ik KIM
1
;
Minsun SONG
;
Suhyun HWANGBO
;
Sungyoung LEE
;
Untack CHO
;
Ju Hyun KIM
;
Maria LEE
;
Hee Seung KIM
;
Hyun Hoon CHUNG
;
Dae Shik SUH
;
Taesung PARK
;
Yong Sang SONG
Author Information
- Publication Type:Original Article
- Keywords: Ovarian neoplasms; Ovarian epithelial cancer; Nomograms; Prognosis; Treatment response; Survival outcomes
- MeSH: Area Under Curve; Disease-Free Survival; Humans; Medical Records; Nomograms; Ovarian Neoplasms; Platinum; Prognosis; Recurrence; ROC Curve
- From:Cancer Research and Treatment 2019;51(3):1144-1155
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC. MATERIALS AND METHODS: We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied. RESULTS: The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively. CONCLUSION: We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
